Researchers at the Georgetown Lombardi Comprehensive Cancer Center have identified that the RAGE protein acts as a primary driver for breast cancer metastasis in older patients. Published in the journal Communications Biology, the study reveals that age-related inflammation activates this cellular receptor, creating an environment that facilitates tumor spread. This discovery points to existing drugs like azeliragon as potential treatments.
The Role of RAGE in Age-Related Metastasis
The study, led by Professor Barry Hudson, focused on triple-negative breast cancer, a highly aggressive form of the disease. Researchers observed that while primary tumors grew at similar rates in both young and aged mice, the older subjects developed significantly more lung metastases.
The culprit is the receptor for advanced glycation end products, known as RAGE. As an organism ages, it naturally produces higher levels of specific inflammatory proteins, such as S100 and HMGB1. These molecules bind to the RAGE receptor, triggering chronic systemic inflammation. This biological shift weakens the body’s immune defenses and actively promotes the dissemination of cancer cells to distant organs. When researchers genetically deleted the RAGE gene in aged mice, the age-associated increase in metastasis was effectively eliminated.
Clinical Validation in Human Patients
To determine if these laboratory findings translated to human biology, the team analyzed medical data from more than 1,000 breast cancer patients. The results confirmed the animal models: patients with higher expression of the AGER gene—which encodes the RAGE protein—and associated inflammatory signatures experienced poorer clinical outcomes. This suggests that aging is not merely a passive background factor in cancer progression but an active biological participant that modifies the body’s environment to support tumor survival and migration.
Potential for Targeted Therapy with Azeliragon
Because RAGE is a known therapeutic target for other age-related conditions, researchers are already investigating existing pharmaceutical options. The drug TTP488, also known as azeliragon, has demonstrated the ability to block RAGE activity.
In laboratory settings, azeliragon successfully inhibited the aggressive behavior of tumor cells when exposed to the blood of aged mice. The drug is currently undergoing clinical trials to evaluate its efficacy in patients with breast cancer who are also receiving chemotherapy. A significant advantage of this approach is that azeliragon has already established a positive safety profile in previous human trials, particularly regarding its impact on cognitive functions.
Shifting Focus to the Tumor Microenvironment
This research signals a transition in oncological strategy. Traditionally, cancer treatment has prioritized targeting internal mutations within individual tumor cells. The findings from the Georgetown Lombardi team emphasize the necessity of addressing the patient’s systemic environment. By focusing on the RAGE pathway, clinicians may eventually be able to disrupt the biological conditions that allow cancer to metastasize in older populations, potentially improving survival rates for a demographic that has historically faced more challenging prognoses.
Key Takeaways
- Mechanistic Discovery: Age-related inflammation activates the RAGE receptor, which accelerates the spread of breast cancer cells to the lungs.
- Evidence Base: The study, published in Communications Biology, utilized data from over 1,000 human patients to validate findings originally observed in mouse models.
- Therapeutic Potential: Azeliragon (TTP488), a drug previously studied for other conditions, is currently being tested in clinical trials for its ability to block RAGE-mediated metastasis in breast cancer patients.
- Systemic Approach: The findings underscore the importance of treating the tumor microenvironment rather than focusing exclusively on internal cellular mutations.
Related reading